Pergamon

Tetrahedron: *Asymmetry* 9 (1998) 993–999

TETRAHEDRON: *ASYMMETRY*

Preparation of cycloalkane-fused dihydropyrimidin-4(3*H*)-one enantiomers †

Zsolt Szakonyi,[a] Ferenc Fülöp,[a,*] Gábor Bernáth,[a] Gabriella Török[b] and Antal Péter[b]

[a]*Institute of Pharmaceutical Chemistry, Albert Szent-Györgyi Medical University, H-6701 Szeged, POB 121, Hungary*
[b]*Department of Inorganic and Analytical Chemistry, Attila József University, H-6701 Szeged, POB 440, Hungary*

Received 12 January 1998; accepted 12 February 1998

Abstract

Racemic *cis*-2-amino-1-cyclopentane- or -cyclohexane-1-carboxylic acid was reacted with (*R*)-α-methylbenzylamine to form homochiral amides **3**, **4** and **8**, **9**. The ring closures of **3**, **4** and **8**, **9** with aryl imidates resulted in cyclopentane *cis*-fused and cyclohexane *cis*- and *trans*-fused dihydropyrimidin-4-one enantiomers with loss of the N-substituent. The absolute configurations were determined by hydrolysis of **5**, **6** and **10**–**13** to the corresponding amino acids. © 1998 Published by Elsevier Science Ltd. All rights reserved.

In the past two decades, increased attention has been directed towards the synthesis of cycloalkane-fused saturated heterocycles,[1] but the methods applied have mostly involved racemic compounds. However, besides their stereochemical and pharmacological interest,[2–4] these heterocycles can also be used for enantioselective syntheses.[5,6]

The aim of the present work was the preparation of the enantiomers of 2-aryl-substituted cycloalkane-fused dihydropyrimidin-4(3*H*)-ones, and determination of their absolute configurations. These compounds possess pronounced pharmacological activity; as an example, (±)-2-(*m*-chlorophenyl)-3,4a,5,6,7,7a-hexahydrocyclopenta[*d*]pyrimidin-4(3*H*)-one (CHINOIN-143) has a strong anti-inflammatory effect.[7] CHINOIN-143 had been earlier resolved via diastereomeric salt formation in two-phase systems by using half an equivalent of dibenzoyltartaric acid.[8] The anti-inflammatory activity of the (−)-enantiomer was twice that of the racemic mixture.[7] The absolute configurations of the enantiomers were not determined.

* Corresponding author. E-mail: Fulop@pharma.szote.u-szeged.hu

† Saturated Heterocycles, Part 261. Part 260: Szakonyi, Z.; Fülöp, F.; Bernáth, G.; Evanics, F.; Riddell, F. G. *Tetrahedron* **1998**, *54*, 1013.

0957-4166/98/$19.00 © 1998 Published by Elsevier Science Ltd. All rights reserved.
PII: S0957-4166(98)00069-X

1. Results and discussion

The pathways for the syntheses of the desired cyclopentane-fused dihydropyrimidin-4-ones **5** and **6** are shown in Scheme 1. After protection of the racemic *cis*-2-amino-1-cyclopentanecarboxylic acid **1**, the Z-amino acid was treated with isobutyl chloroformate, and the resulting anhydride was reacted with (+)-(*R*)-α-methylbenzylamine, resulting in **2**.[9] The protecting group of **2** was removed by treatment with hydrogen bromide. The separation of racemic *cis*-2-amino-1-cyclopentanecarboxylic acid was accomplished by the procedure applied by Goodman et al. to Boc-*trans*-2-amino-1-cyclopentanecarboxylic acid.[10] The diastereomers **3** and **4** were separated by flash chromatography.



Scheme 1. i: 10% aq. NaOH, $PhCH_2OCOCl$ (yield: 95%); ii: TEA, ClCOO*i*Bu, THF/−10°C, then (+)-(*R*)-$H_2NCH(Me)Ph$/−10°C, 5 h (yield: 81%); iii: cc. AcOH, HBr, 1 h, then 20% aq. NaOH (yield: 89%); iv: flash chromatography (MeOH:EtOAc=4:1); v: ethyl *m*-chlorobenzimidate, cat. H^+/EtOH, reflux for 5 days

When **3** and **4** were heated with ethyl *m*-chlorobenzimidate in ethanol in the presence of a catalytic amount of acetic acid, **5** and **6** were obtained in high enantiomeric purity.

Racemic 2-(*m*-chlorophenyl)-3,4a,5,6,7,7a-hexahydrocyclopenta[*d*]pyrimidin-4(3*H*)-one and its analogues were synthesized by reaction of the corresponding β-amino acid or its derivatives with ethyl benzimidates, by reaction of orthoesters with 2-amino-1-cycloalkanecarboxamides, or by ring enlargement of cycloalkane-fused azetidinones with imidates.[1,11] In the reactions of the β-amino acid derivatives with benzimidates, the first step is the formation of an amidine intermediate; the subsequent nucleophilic attack of the imino group of the amidine on the carbonyl group results in the desired pyrimidin-4(3*H*)-ones. The same mechanism was found in the ring enlargement of cycloalkane-fused azetidinones on reaction with benzimidates.[12] In the reaction of **3**, the intermediate amidine **7** was isolated (mp: 218–221°C).

The absolute configurations of the prepared compounds were determined by hydrolysis of **5** and **6** to the corresponding amino acid, which was identified by HPLC.[13–17] It is interesting that the absolute configuration of the enantiomer with the higher anti-inflammatory activity corresponds to that of cispentacin [(1*R*,2*S*)-2-amino-1-cyclopentanecarboxylic acid], an antibiotic isolated from *Bacillus cereus* and *Streptomyces setonii*[18–22] and enantioselectively prepared earlier.[23–25]



7



(-)-CHINOIN 143



cispentacin

In the ring-closure reaction of the cyclohexane-fused homologue, C-1 epimerization was observed (Scheme 2). Separation of the epimers **10**, **11** and **12**, **13** resulted in all four possible enantiomers. It is noteworthy that *cis*→*trans* isomerization is also possible for the cyclopentane derivatives, but the *trans* isomer (in accordance with earlier observations on *trans*-1,2-disubstituted 1,3-difunctional cyclopentane derivatives) does not undergo hetero-ring formation.[1]



Scheme 2. i: Ethyl benzimidate, cat. H^+/EtOH, 5 days; ii: flash chromatography (hexane:EtOAc=6:4)

The yields of the cyclohexane-fused pyrimidin-4(3*H*)-ones were relatively low, probably in consequence of their ring opening to afford amidines[26] in the course of the separation of the isomers on a silica gel column. The absolute configurations of the prepared compounds were determined by hydrolysis of **10**–**13** to the corresponding amino acids, which were identified by HPLC.[13–17]

2. Experimental

The NMR spectra were recorded on a BRUKER AVANCE DRX 400 spectrometer, using a '5 mm inverse Z gradient' probehead. The samples were dissolved in $CDCl_3$ containing 0.03% TMS as a reference. The number of scans was usually 64 for ^1H and 2K for ^{13}C spectra. All NMR measurements were carried out at 300 K.

HPLC measurements were performed on a Waters system consisting of an M-600 low-pressure gradient pump, an M-996 photodiode array detector and a Millenium 2010 Chromatography Manager data system (Waters Chromatography, Division of Millipore, Milford, MA, USA). The column used for indirect separation was a Vydac 218TP54 C_{18} column (250×4.6 mm I.D.), 5 μm particle size (The Separations Group, Hesperia, CA, USA), and for direct separation a CHIRAL-AGP column (100×4.0

mm I.D.), 5 μm particle size (ChromTech AB, HŠgersten, Sweden), and a cellulose triacetate column (250×10 mm I.D.), 10 μm particle size (Merck, Darmstadt, Germany).

GC measurements were performed on a Crompack CP-9002 system consisting of a Flame Ionization Detector 901A and Maestro II Chromatography data system (Chrompack International B.V., Middelburg, The Netherlands). The column used for direct separation was a CHIRASIL-DEX CB column (2500×0.25 mm I.D.). Optical rotation values were obtained with a Perkin–Elmer 341 polarimeter.

Melting points were determined on a Kofler apparatus and are uncorrected.

2.1. Chemicals and reagents

2,3,4,6-Tetra-*O*-acetyl-β-D-glucopyranosylisothiocyanate (GITC) was purchased from Aldrich (Steinheim, Germany); trifluoroacetic acid (TFA), NaH_2PO_4 and NaOH of analytical reagent grade and HPLC-grade methanol, ethanol and 2-propanol were obtained from Merck (Darmstadt, Germany). A 0.1% aqueous solution of TFA was prepared with Milli-Q water purified further by filtering on a 0.45 μm Millipore filter, type HV (Molsheim, France). A 0.01 M NaH_2PO_4 buffer (pH=5.0) was prepared with Milli-Q water. A Radelkis OP/20811 pH meter (Budapest, Hungary) equipped with a combined glass–calomel electrode was employed for pH measurements. The mobile phases were prepared by mixing a 0.1% aqueous solution of TFA or 0.01 M NaH_2PO_4 buffer or water with methanol, ethanol or 2-propanol. The eluent was degassed in an ultrasonic bath, and during the analysis helium gas was bubbled through the solution.

2.2. cis-*2-Benzyloxycarbonylamino-1-cycloalkanecarbonyl-(+)-(*R*)-α-methylbenzylamines*

A quantity (20 mmol) of *cis*-2-benzyloxycarbonylamino-1-cyclopentane- or -cyclohexanecarboxylic acid was dissolved in dry THF (70 ml) and the solution was cooled to −10°C. Triethylamine (2.02 g, 20 mmol) and isobutyl chloroformate (2.73 g, 20 mmol) were added with vigorous stirring; after stirring for another 10 minutes, (+)-(*R*)-α-methylbenzylamine (2.42 g, 20 mmol) dissolved in THF (20 ml) was added dropwise at −10°C. Stirring was continued for 5 hrs, and the mixture was then allowed to stand overnight at room temperature. After evaporation of the THF, the residue was dissolved in $CHCl_3$ (200 ml) and extracted with a 5% solution of aqueous HCl (2×50 ml) and a 5% solution of NaOH (1×50 ml). The organic phase was dried over Na_2SO_4 and evaporated. The crude products were used for the preparation of **3**, **4**, **8** and **9** without further purification.[10]

2.3. *[(1*R,*2*S*)- and (1*S,*2*R*)*-cis-*2-Amino-1-cyclopentanecarbonyl]-(+)-(*R*)-α-methylbenzylamine (**3** and **4**), [(1*R,*2*S*)- and (1*S,*2*R*)*-cis-*2-amino-1-cyclohexanecarbonyl]-(+)-(*R*)-α-methylbenzylamine (**8** and **9**)*

Five equivalents of HBr, as a 20% solution in glacial acetic acid, was added to a diastereomeric mixture of 2-Z-amino-1-carboxamides (10 mmol) and the mixture was stirred for 50 minutes at room temperature. The clarified solution was extracted with diethyl ether (2×60 ml). The aqueous phase was made alkaline with a 20% solution of NaOH and extracted with $CHCl_3$ (3×50 ml). The organic phase was dried over Na_2SO_4 and evaporated, yielding the products as yellow oils. The diastereomeric mixtures were separated by flash chromatography ($CHCl_3$:MeOH=4:1) and the separated diastereomers were obtained as pale-yellow crystalline products.

The fast-eluting isomer **3** [1.11 g, 48%; $[\alpha]_D^{20} = +108$ (c=0.1, MeOH); ee>99%]: ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.23–7.35 (m, 5H, Ph), 7.20 (bd, 1H, *J*=6.4 Hz, NH), 5.10 (m, 1H, PhCHN), 3.47 (m,

1H, H–C2), 2.59 (m, 1H, H–C1), 1.52–1.96 (m, 6H, 3×CH_2), 1.47 (d, 3H, *J*=6.9 Hz, Me). Analysis: calculated for $C_{14}H_{20}N_2O$: C, 72.38; H, 8.68; N, 12.06; found: C, 72.12; H, 8.49; N, 12.15.

The slow-eluting isomer **4** [0.95 g, 41%; $[\alpha]_D^{20}$ = +124 (c=0.1, MeOH); ee>99%]: ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.22–7.33 (m, 5H, Ph), 7.16 (bd, 1H, *J*=6.4 Hz, NH), 5.14 (m, 1H, PhCHN), 3.51 (m, 1H, H–C2), 2.53 (m, 1H, H–C1), 1.50–2.00 (m, 6H, 3×CH_2), 1.48 (d, 3H, *J*=6.9 Hz, Me). Analysis: calculated for $C_{14}H_{20}N_2O$: C, 72.38; H, 8.68; N, 12.06; found: C, 72.16; H, 8.79; N, 12.46.

The fast-eluting isomer **8** [1.06 g, 43%; $[\alpha]_D^{20}$ = +80 (c=0.1, MeOH); ee>99%]: ^{1}H NMR (400 MHz, $CDCl_3$): δ 8.68 (bd, 1H, *J*=6.8 Hz, NH), 7.20–7.34 (m, 5H, Ph), 5.11 (m, 1H, PhCHN), 3.29 (m, 1H, H–C2), 2.38 (m, 1H, H–C1), 1.33–1.87 (m, 8H, 4×CH_2), 1.45 (d, 3H, *J*=6.9 Hz, Me). Analysis: calculated for $C_{15}H_{22}N_2O$: C, 73.13; H, 9.00; N, 11.37; found: C, 73.29; H, 8.69; N, 11.35.

The slow-eluting isomer **9** [0.98 g, 40%; $[\alpha]_D^{20}$ = +95 (c=0.1, MeOH); ee>99%]: ^{1}H NMR (400 MHz, $CDCl_3$): δ 8.76 (bd, 1H, *J*=6.5 Hz, NH), 7.20–7.31 (m, 5H, Ph), 5.12 (m, 1H, PhCHN), 3.28 (m, 1H, H–C2), 2.35 (m, 1H, H–C1), 1.34–1.91 (m, 8H, 4×CH_2), 1.45 (d, 3H, *J*=6.9 Hz, Me). Analysis: calculated for $C_{15}H_{22}N_2O$: C, 73.13; H, 9.00; N, 11.37; found: C, 73.32; H, 8.88; N, 11.53.

To determine the enantiomeric purity, **3**, **4** and **8**, **9** were derivatized with GITC and subsequently separated by HPLC on a Vydac column (a 0.1% aqueous solution of TFA:methanol=45:55 v/v; flow rate, 0.8 ml/min; detection at 250 nm).

*2.4. (−)-(4a*R*,7a*S*)- and (+)-(4a*S*,7a*R*)-2-(*m*-Chlorophenyl)-3,4a,5,6,7,7a-hexahydrocyclopenta[*d*]-pyrimidin-4(3*H*)-one (**5** and **6**)*

To a solution of **3** or **4** (1.00 g, 4.3 mmol) in 40 ml of dry ethanol, ethyl *m*-chlorobenzimidate (0.47 g, 4.3 mmol) and one drop of glacial acetic acid were added and the mixture was refluxed for 6 days. The solution was then evaporated to dryness, and the residue was dissolved in 50 ml of 3% aqueous HCl solution and extracted with $CHCl_3$ (2×20 ml). The aqueous phase was made alkaline with saturated $NaHCO_3$ solution and extracted with $CHCl_3$ (3×30 ml). The combined organic phase was dried (Na_2SO_4), and evaporated, and the crystalline residue was recrystallized from isopropyl ether.

Compound **5** (0.56 g, 52%): ^{1}H NMR (400 MHz, $CDCl_3$): δ 8.61 (bs, 1H, NH), 7.36–7.82 (m, 4H, *m*ClPh), 4.28 (m, 1H, H–C7a), 2.75 (m, 1H, H–C4a), 1.64–2.27 (m, 6H, 3×CH_2). Analysis: calculated for $C_{13}H_{13}ClN_2O$: C, 62.78; H, 5.27; N, 11.26; found: C, 62.39; H, 5.43; N, 11.41; mp: 120–122°C (lit.[7]: 117–118°C); $[\alpha]_D^{20}$ = −55 (c=1.0, n HCl, lit.[7]: −54); ee>98%.

Compound **6** (0.58 g, 54%): the ^{1}H NMR spectrum of **6** was identical to that of **5**. Analysis: calculated for $C_{13}H_{13}ClN_2O$: C, 62.78; H, 5.27; N, 11.26; found: C, 62.48; H, 5.52; N, 11.12; mp: 122–123°C (lit.[7]: 117–118°C); $[\alpha]_D^{20}$ = +54 (c=1.0, n HCl, lit.[7]: +54); ee>98%.

To determine the enantiomeric purity, direct separation of **5** and **6** was performed on a CHIRAL-AGP column (2-propanol:NaH_2PO_4 (0.01 M, pH=5.0) 3:97 v/v; flow rate, 0.9 ml/min; detection at 246 nm).

*2.5. (−)-(4a*R*,8a*S*)- and (+)-(4a*S*,8a*S*)-2-Phenyl-3,4,4a,5,6,7,8,8a-octahydroquinazolin-4(3*H*)-one (**10** and **11**), (+)-(4a*S*,8a*R*)- and (−)-(4a*R*,8a*R*)-2-phenyl-3,4,4a,5,6,7,8,8a-octahydroquinazolin-4(3*H*)-one (**12** and **13**)*

The reaction was performed on **8** or **9** (1.20 g, 4.9 mmol) and ethyl benzimidate (0.73 g, 4.9 mmol), as described for **5** and **6**. The diastereomeric mixtures obtained were separated on a silica gel column by flash chromatography (hexane:EtOAc=6:4) and the separated diastereomers were recrystallized from isopropyl ether.

Compound **10** (0.30 g, 27%): ^{1}H NMR (400 MHz, $CDCl_3$): δ 8.43 (bs, 1H, NH), 7.42–7.78 (m, 5H, Ph), 3.90 (m, 1H, H–C8a), 2.69 (m, 1H, H–C4a), 1.44–2.11 (m, 8H, 4×CH_2). Analysis: calculated for $C_{14}H_{16}N_2O$: C, 73.66; H, 7.06; N, 12.27; found: C, 73.81; H, 7.15; N, 12.08; mp: 170–172°C; $[\alpha]_D^{20} = -75$ (c=0.1, MeOH); ee>98%.

Compound **11** (0.15 g, 13%): ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.49 (bs, 1H, NH), 7.41–7.78 (m, 5H, Ph), 3.24 (m, 1H, H–C8a), 2.40 (overlapping m, 1H, H–C4a), 1.27–2.40 (m, 8H, 4×CH_2). Analysis: calculated for $C_{14}H_{16}N_2O$: C, 73.66; H, 7.06; N, 12.27; found: C, 73.54; H, 7.02; N, 12.43; mp: 200–202°C; $[\alpha]_D^{20} = +107$ (c=0.1, MeOH); ee>98%.

Compound **12** (0.32 g, 29%): the ^{1}H NMR spectrum of **12** was identical to that of **10**. Analysis: calculated for $C_{14}H_{16}N_2O$: C, 73.66; H, 7.06; N, 12.27; found: C, 73.78; H, 7.13; N, 12.21; mp: 172–174°C; $[\alpha]_D^{20} = +76$ (c=0.1, MeOH); ee>98%.

Compound **13** (0.19 g, 17%): the ^{1}H NMR spectrum of **13** was identical with that of **11**. Analysis: calculated for $C_{14}H_{16}N_2O$: C, 73.66; H, 7.06; N, 12.27; found: C, 73.75; H, 7.27; N, 12.45; mp: 200–203°C; $[\alpha]_D^{20} = -106$ (c=0.1, MeOH); ee>98%.

To determine the enantiomeric purity, direct separation of **10** and **12** was performed by GC on a CHIRASIL-DEX CB column (170°C, 80 kPa), and that of **11** and **13** by HPLC on a cellulose triacetate column (ethanol:water=75:25 v/v; flow rate, 0.8 ml/min; temperature, 50°C; detection at 246 nm).

2.6. General method for the hydrolysis, derivatization and absolute configuration determination

A quantity (0.5 mg) of **5**, **6** or **10**–**13** was dissolved in 100 μl methanol, and 200 μl aqueous NaOH solution (5 M) was added to each solution. The compounds were hydrolysed at 40°C for 6 days. The reaction was stopped by adding aqueous HCl solution (2 M) until pH≤7 was reached. 1 mg/ml solutions of **1**, cispentacin, (±)-*cis*- and (±)-*trans*-2-amino-1-cyclohexanecarboxylic acid (*cis*- and *trans*-ACHC), the 1*R*,2*S* and 1*S*,2*S* enantiomers of ACHC and 100 μl of solutions of each hydrolysed compound were used for derivatization with GITC by the method of Nimura et al.[22]

The absolute configurations of **5**, **6** and **10**–**13** were determined by comparison of the spectra and chromatograms of the GITC derivatives of **5**, **6** (Vydac, a 0.1% aqueous solution of TFA:methanol=57.5:42.5 v/v; flow rate, 0.8 ml/min; detection at 250 nm) and **10**–**13** (Vydac, a 0.1% aqueous solution of TFA:methanol=50:50 v/v; flow rate, 0.8 ml/min; detection at 250 nm), with those of the GITC derivatives of cispentacin, and the 1*R*,2*S* and 1*S*,2*S* enantiomers of ACHC.[23]

Acknowledgements

Financial support from OTKA (grant T 20454) and MKM (grant FKFP 0910/1997 and 0087/1997) is gratefully acknowledged. A. P. expresses his thanks to Merck Kft., Budapest for the cellulose triacetate column.

References

1. Fülöp, F.; Bernáth, G.; Pihlaja, K. *Adv. Heterocyclic Chem*. **1998**, *69*, 349.
2. Bernáth, G. *Acta Chim. Hung.— Models in Chemistry* **1992**, *129*, 107.
3. Bernáth, G. *Bull. Soc. Chim. Belg*. **1994**, *103*, 509.
4. Fülöp, F. *Acta Chim. Hung.— Models in Chemistry* **1994**, *131*, 647.
5. Eliel, E. L.; He, X.-C. *J. Org. Chem*. **1990**, *55*, 2114.
6. Alberola, A.; Andrés, C.; Pedrosa, R. *Synlett* **1990**, 763.

7. Bernáth, G.; Gera, L.; Göndös, G.; Ecsery, Z.; Hermann, M.; Szentiványi, M.; Janvári, L. *Hung. Pat*. 172460 (1979), [*Chem. Abstr*. **1981**, *94*, 175144].
8. Ács, M.; Fogassy, E.; Faigl, F. *Tetrahedron* **1985**, *41*, 2465.
9. Bernáth, G.; Gera, L.; Göndös, G.; Pánovics, I.; Ecsery, Z. *Acta Chim. Hung*. **1976**, *89*, 61.
10. Yamazaki, T.; Zhu, Y.; Probstl, A.; Chadha, R. K.; Goodman, M. *J. Org. Chem*. **1991**, *56*, 6644.
11. Szakonyi, Z.; Fülöp, F.; Bernáth, G.; Sohár, P. *Heterocycles* **1996**, *42*, 625.
12. Bernáth, G.; Tóth, G.; Fülöp, F.; Göndös, G.; Gera, L. *J. Chem. Soc., Perkin Trans. 1* **1979**, 1765.
13. Péter, A.; Fülöp, F.; *J. Chromatogr. A* **1995**, *715*, 219.
14. Csomós, P.; Kanerva, L. T.; Bernáth, G.; Fülöp, F. *Tetrahedron: Asymmetry* **1996**, *7*, 1789.
15. Kanerva, L. T.; Csomós, P.; Sundholm, O.; Bernáth, G.; Fülöp, F. *Tetrahedron: Asymmetry* **1996**, *7*, 1705.
16. Nimura, N.; Ogura, H.; Kinoshita,T. *J. Chromatogr*. **1980**, *202*, 375.
17. Péter, A.; Török, G.; Csomós, P.; Péter, M.; Bernáth, G.; Fülöp F. *J. Chromatogr. A* **1997**, *761*, 103.
18. Capobianco, J. O.; Zakula, D.; Coen, M. L.; Goldman, R. C. *Biochem. Biophys. Res. Commun*. **1993**, *190*, 1037.
19. Oki, T.; Hirano, M.; Tomatsu, K.; Numata, K.; Kamei, H. *J. Antibiotics* **1989**, *42*, 1756.
20. Konishi, M.; Nishio, M.; Saitoh, K.; Miyaki, T.; Oki, T.; Kawaguchi, H. *J. Antibiotics* **1989**, *42*, 1749.
21. Iwamoto, T.; Tsujii, E.; Ezaki, M.; Fujie, A.; Hashimoto, S.; Okuhara, M.; Kohsaka, M.; Imanaka, H.; Kawabata, K.; Inamoto, Y.; Sakane, K. *J. Antibiotics* **1990**, *43*, 1.
22. Kawabata, K.; Inamoto, Y.; Sakane, K.; Iwamoto, T.; Hashimoto, S. *J. Antibiotics* **1990**, *43*, 513.
23. Konosu, T.; Oida, S. *Chem. Pharm. Bull*. **1993**, *41*, 1012.
24. Davies, S. G.; Ichihara, O.; Walters, I. A. S. *Synlett* **1993**, 461. Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, A. S. *J. Chem. Soc., Perkin Trans. 1* **1994**, 1411.
25. Enders, D.; Wiedemann, J.; Bettray, W. *Synlett* **1995**, 369. Enders, D.; Wiedemann, J. *Liebigs Ann*. **1997**, 699.
26. Göndös, G.; Szécsényi, I.; Gera, L. *J. Planar Chromatogr*. **1989**, *2*, 163.